Business Context and Reporting Period
This Form 8-K Current Report was filed by Contineum Therapeutics, Inc. (CTNM) on May 24, 2024. The Company is a Delaware corporation with its principal executive offices in San Diego, California, and its Class A Common Stock trades on the Nasdaq Global Select Market. The filing primarily addresses the adoption of a new Executive Severance Plan and related executive agreements.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on corporate governance and executive compensation arrangements.
Material Changes
The material change reported is the adoption of the Contineum Therapeutics, Inc. Executive Severance Plan on May 24, 2024. On May 28, 2024, the Company's named executive officers entered into Participation Agreements under this new plan, which supersedes and replaces any existing employment or severance agreements. The executives involved include:
- Tier 1 Participant: Carmine Stengone, Chief Executive Officer and President.
- Tier 2 Participants: Daniel Lorrain, Ph.D., Chief Scientific Officer, and Peter Slover, Chief Financial Officer.
Guidance, Outlook, and Management Commentary
The filing provides no financial guidance, outlook, or general management commentary regarding the Company's business strategy or market conditions. The document details the specific terms of the Severance Plan, which includes:
- Non-Change in Control Termination: Eligible participants receive a lump sum cash payment (12 months of base salary for Tier 1/2; 6 months for Tier 3) plus a pro-rated bonus, and health benefit continuation for a similar duration.
- Change in Control Termination: Benefits are enhanced, including a lump sum cash payment (150% of salary+bonus for Tier 1; 100% for Tier 2; 75% for Tier 3), full vesting of time-based equity awards, and accelerated vesting of performance-based awards at the "target" level.
- Arbitration: The Company entered into standard mutual arbitration agreements with the participating executives.
Investor Verification Checklist
- Verify the specific terms of the Executive Severance Plan by reviewing Exhibit 10.1 attached to the filing.
- Confirm the impact of the new Participation Agreements on the Company's future compensation liabilities.
- Review the mutual arbitration agreements (Exhibit 10.2) to understand dispute resolution mechanisms for executives.
- Note that this filing contains no financial results; refer to the most recent 10-Q or 10-K for financial health metrics.